Trial Profile
Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure IND117394 12/28/12
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Orthostatic hypotension
- Focus Therapeutic Use
- Acronyms NETAF
- 18 Aug 2023 Status changed from active, no longer recruiting to completed.
- 13 Apr 2022 Planned End Date changed from 1 Mar 2022 to 1 Apr 2023.
- 16 Feb 2022 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.